Accelerated Discovery of Macrocyclic CDK2 Inhibitor QR-6401 by Generative Models and Structure-Based Drug Design
Lists
Only you see this
Abstract
Selective CDK2 inhibitors have the potential to provide effective therapeutics for CDK2-dependent cancers and for combating drug resistance due to high cyclin E1 (CCNE1) expression intrinsically or CCNE1 amplification induced by treatment of CDK4/6 inhibitors. Generative models that take advantage of deep learning are being increasingly integrated into early drug discovery for hit identification and lead optimization. Here we report the discovery of a highly potent and selective macrocyclic CDK2 inhibitor QR-6401 (<b>23</b>) accelerated by the application of generative models and structure-based drug design (SBDD). QR-6401 (<b>23</b>) demonstrated robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration.
BibTeX
@inproceedings{yu2023accelerated,
author = {Yang Yu and Junhong Huang and Hu He and Jing Han and Geyan Ye and Tingyang Xu and Xianqiang Sun and Xiumei Chen and Xiaoming Ren and Chunlai Li and Huijuan Li and Weitong Huang and Yang Liu and Xinjuan Wang and Yongzhi Gao and Nianhe Cheng and Na Guo and Xibo Chen and Jianxia Feng and Yuxia Hua and Chong Liu and Guoyun Zhu and Zhi Xie and Lili Yao and Wenge Zhong and Xinde Chen and Wei Liu and Hailong Li and Hailong Li and Hailong Li},
title = {{Accelerated Discovery of Macrocyclic CDK2 Inhibitor QR-6401 by Generative Models and Structure-Based Drug Design}},
booktitle = {ACS},
year = {2023},
doi = {10.1021/acsmedchemlett.2c00515},
}Loading related content...